Good point. One would think that Merck would want to know how the Combo trial with Keytruda was panning out as well as NWBO as it would increase the BO offer.
Why would extending warrants be a result of a perspective b/o when a b/o will buy all shares and warrants in their entirety ?
I think there is a deal in the offing , actually I think its already done, there has to be its unthinkable that LP hasn't built a relationship with key cancer pharma players.
She has the TLD and probably more than enough data to know just how good the results are and Merck will not require an explanation of the value of positive data.
The share price on the day the deal is struck will have zero to do with the price an acquirer pays therefore warrant extensions or not everything is priced on a fully diluted basis .
News 
Market Data 
Discover 
AI
